Dulaglutide Tracker App
Track Trulicity Doses, HbA1c, and Weekly Progress in Shotlee
Dulaglutide (Trulicity) is a once-weekly GLP-1 receptor agonist for type 2 diabetes, available in four doses from 0.75 mg to 4.5 mg. As a GLP-1 Fc fusion protein with a 5-day half-life, it delivers consistent weekly GLP-1 receptor stimulation with a hidden-needle autoinjector. The REWIND trial demonstrated cardiovascular benefit across a broad T2D population. Track every weekly dose and lab result in Shotlee.
What Is Dulaglutide?
Dulaglutide (brand name Trulicity) is a GLP-1 Fc fusion protein developed by Eli Lilly and approved by the FDA in September 2014. Unlike GLP-1 analogues (liraglutide, semaglutide) which are structurally modified forms of native GLP-1, dulaglutide consists of two GLP-1 molecules linked to a modified human IgG4 Fc region. This architecture reduces renal clearance and extends the half-life to approximately 5 days — enabling reliable once-weekly dosing.
The mechanism is identical to other GLP-1 receptor agonists: stimulation of the GLP-1 receptor increases glucose-dependent insulin secretion, reduces glucagon, slows gastric emptying, and reduces hypothalamic appetite signals. Dulaglutide is delivered via a single-dose, pre-filled autoinjector with a hidden needle — a feature that has made it popular among patients with needle aversion who would otherwise avoid injectable GLP-1 therapy entirely.
Dulaglutide Dose Schedule
Initiation dose to improve tolerability. Administer once weekly on the same day. Establish injection day routine from week 1.
Standard maintenance dose. AWARD-1: -1.51% HbA1c. Adequate for most patients with T2D.
For patients requiring additional HbA1c reduction beyond 1.5 mg. Added in 2020 US label update.
Maximum approved dose. AWARD-11 showed additional -0.3% HbA1c vs 1.5 mg. Highest weight reduction in the dulaglutide range.
Dulaglutide Clinical Data Highlights
What to Track in Shotlee
Weekly dulaglutide injections pair well with weekly check-ins — use Shotlee to build a consistent weekly tracking routine.
Protocol FAQs
Dulaglutide (Trulicity) is a GLP-1 Fc fusion protein; semaglutide (Ozempic/Wegovy) is a GLP-1 analogue. Both are once-weekly GLP-1 receptor agonists. Head-to-head trials (SUSTAIN 7) show semaglutide achieves greater HbA1c reduction (-1.8% vs -1.4%) and weight loss (-6.5 kg vs -3.0 kg) at comparable doses.
The REWIND trial (9,901 T2D patients, 5.4 years) showed dulaglutide reduced 3-point MACE by 12% vs placebo. This included a broad population — 31.5% had no prior CV event — extending cardiovascular benefit beyond the high-risk populations studied in earlier GLP-1 trials.
Yes. Biosimilar dulaglutide has been approved in some markets, providing a lower-cost alternative to branded Trulicity. Availability varies by country and insurance coverage. Biosimilar versions should have the same clinical effect as the originator.
Once weekly on the same day each week. The day can be changed as long as doses remain at least 3 days apart. Use Shotlee to log your injection day and receive weekly reminders.
Nausea (12–21%), diarrhoea (8–14%), vomiting (5–9%), and abdominal pain (9–11%) are most common during dose initiation and escalation. These typically resolve within 4–6 weeks. Log side effects in Shotlee with timing and severity to track resolution.
Track Your Dulaglutide Protocol in Shotlee
Log weekly injections, HbA1c, cardiovascular markers, and side effects — free in Shotlee.